Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $65.
Share
Why It Matters
A big investment research firm started following LB Pharmaceuticals and thinks it looks good. When experts start paying attention to a company, it often means they see something worth watching.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.